BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Interest Expense

Cost of servicing the company's debt during the period.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of $21.71M rose 0.6% year over year, ahead of the -20.2% change in trailing-twelve-month interest expense. Sequentially, it rose 9.8% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.

Context

  • Interest expense amounted to 9.0% of revenue in FY2025, down 12.8 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.6% holds above the trailing-twelve-month pace of -20.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$21.71M+9.8% QoQ
Last fiscal yearDec 2025
$78.87M-19.9% YoY
LTMJun 2026
$75.29M-20.2% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%——
1 year-19.9%——
3-year CAGR-7.3%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
78.87M USD
Year-over-year change
-19.9%
4-year CAGR
+7.4%

Interest Expense vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 8.0% of revenue for BCRX, versus a peer median of 0.0%.
BCRX Competitors
Interest Expense for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$75.29M USD-20.2%-7.3%8.0%
PHVSPharvaris N.V.LTM Sep 2026€87.82K EUR———
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD——0.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding BCRX) ———0.0%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.